Raymond James Financial’s Bio-Rad Laboratories Class A BIO Stock Holding History

Raymond James Financial’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10M	Buy	35,894 +2,788	+8%	+$803K	﹤0.01%	2023
2025 Q4	$10M	Buy	33,106 +5,867	+22%	+$1.83M	﹤0.01%	1960
2025 Q3	$7.64M	Buy	27,239 +4,665	+21%	+$1.27M	﹤0.01%	2133
2025 Q2	$5.45M	Buy	22,574 +7,402	+49%	+$1.75M	﹤0.01%	2324
2025 Q1	$3.7M	Sell	15,172 -409	-3%	-$123K	﹤0.01%	2527
2024 Q4	$5.12M	Buy	+15,581	New	+$5.29M	﹤0.01%	2321

Other funds holding BIO

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James Financial's BIO Position: Q1 2026 in Review

Raymond James Financial increased its Bio-Rad Laboratories Class A (BIO) stake by 8.4% in Q1 2026, buying an estimated $803K and bringing the position to 35,894 shares worth $10M. The position accounts for ﹤0.01% of the portfolio, ranked #2023.

Raymond James Financial first reported a position in BIO in Q4 2024 and has held it in 6 quarters since. The position peaked at $10M in Q4 2025. 393 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

Raymond James Financial held 35,894 shares of Bio-Rad Laboratories Class A worth $10M as of Q1 2026.
Raymond James Financial bought 2,788 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $803K.
Bio-Rad Laboratories Class A made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #2023 holding.
Raymond James Financial first reported a position in Bio-Rad Laboratories Class A in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's Bio-Rad Laboratories Class A position peaked at $10M in Q4 2025.
393 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.